Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total Oncology Franchise Product Sales by Year
Total Oncology Franchise Product Sales ($M) ($M)
Gilead Sciences Total Oncology Franchise Product Sales: $3,236M in FY2025, down 1.6% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Oncology Franchise Product Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,236 | -1.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 3,289 | +12.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 2,932 | +37.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 2,139 | +71.0% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 1,251 | – | Form 10-K (filed 2024-02-23) ↗ |
Breakdown
What makes up total Oncology Franchise Product Sales
- Total Oncology Franchise Product Sales — U.S. sales ($M)1,626 · FY2025
- Total Oncology Franchise Product Sales — Europe sales ($M)1,102 · FY2025
- Total Oncology Franchise Product Sales — Rest of World sales ($M)508 · FY2025
- Total Oncology Franchise Product Sales — Worldwide YoY growth (%)-2.0% · FY2025
- Total Kite Cell Therapy Product Sales ($M)1,839 · FY2025
- Trodelvy (sacituzumab govitecan-hziy — TROP-2 ADC) ($M)1,397 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Total Oncology Franchise Product Sales ($M), annual FY2021–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/onc-total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.